MAPS and the Psychedelic Renaissance

Its founder's own research career traces back to a follow-up study on a famous 1962 religious experiment involving psilocybin given to divinity students. Despite decades of accumulated research culminating in the organisation's work, US regulators formally rejected an application for MDMA-assisted therapy as recently as August 2024 — a still-unresolved, live regulatory question.

Rick Doblin's founding of MAPS (1986); the FDA's rejection of MDMA-assisted therapy (August 2024)

A research organisation founded in 1986 that has driven decades of renewed scientific study into psychedelic-assisted therapy.

Sources and verificationThe reading is attributed above

No formal citations for this entry yet. The reading above carries its own attribution.